Skip to main content

Has pomalidomide been funded by Pharmac as a third-line treatment for relapsed or refractory multiple myeloma, if not, is it under consideration for funding?

Answered Question 18910 (2026)
Question published
Reply lodged
Bookmark

Asked by

Ayesha Verrall

List MP · Labour Party

Question

  • Has pomalidomide been funded by Pharmac as a third-line treatment for relapsed or refractory multiple myeloma, if not, is it under consideration for funding?

Answered by

Hon David Seymour

Member for Epsom · ACT Party · Associate Minister of Health

Answer

Yes, pomalidomide is funded by Pharmac as a second or later line treatment. I am advised by Pharmac it has been funded since 1 August 2024. I refer the Member to the following link for more information: https://www.pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-increase-access-to-lenalidomide-and-pomalidomide-through-a-brand-change-for-lenalidomide